Institute of Endocrinology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel.
Eur J Endocrinol. 2013 Jul 29;169(3):313-20. doi: 10.1530/EJE-13-0228. Print 2013 Sep.
Hypothyroidism during pregnancy has been associated with adverse obstetrical outcomes. Most studies have focused on subjects with a mild or subclinical disorder. The aims of the present study were to determine the relative rate of severe thyroid dysfunction among pregnant women with hypothyroidism, identify related factors and analyse the impact on pregnancy outcomes.
A retrospective case series design was employed.
The study group included 101 pregnant women (103 pregnancies) with an antenatal serum TSH level >20.0 mIU/l identified from the 2009-2010 computerised database of a health maintenance organisation. Data were collected from the medical records. Pregnancy outcomes were compared with those of a control group of 205 euthyroid pregnant women during the same period.
The study group accounted for 1.04% of all insured pregnant women with recorded hypothyroidism during the study period. Most cases had an autoimmune aetiology. All women were treated with levothyroxine (L-T₄) during pregnancy. Maximum serum TSH level measured was 20.11-150 mIU/l (median 32.95 mIU/l) and median serum TSH level 0.36-75.17 mIU/l (median 7.44 mIU/l). The mean duration of hypothyroidism during pregnancy was 21.2 ± 13.2 weeks (median 18.5 weeks); in 36 cases (34.9%), all TSH levels during pregnancy were elevated. Adverse pregnancy outcomes included abortions in 7.8% of the cases, premature deliveries in 2.9% and other complications in 14.6%, with no statistically significant differences from the control group. Median serum TSH level during pregnancy was positively correlated with the rate of abortions+premature deliveries and rate of all pregnancy-related complications (P<0.05).
Abortions and premature deliveries occur infrequently in women with severe hypothyroidism. Intense follow-up and L-T₄ treatment may improve pregnancy outcomes even when target TSH levels are not reached.
甲状腺功能减退症在怀孕期间与不良产科结局有关。大多数研究都集中在轻度或亚临床疾病的患者上。本研究的目的是确定患有甲状腺功能减退症的孕妇中严重甲状腺功能障碍的相对发生率,确定相关因素,并分析对妊娠结局的影响。
采用回顾性病例系列设计。
从一家健康维护组织的 2009-2010 年计算机数据库中,选择产前血清 TSH 水平>20.0 mIU/l 的 101 例孕妇(103 例妊娠)进行研究。从病历中收集数据。将妊娠结局与同期 205 例甲状腺功能正常孕妇的对照组进行比较。
研究组占研究期间所有记录有甲状腺功能减退症的参保孕妇的 1.04%。大多数病例为自身免疫性病因。所有孕妇在怀孕期间均接受左甲状腺素(L-T₄)治疗。测量的最大血清 TSH 水平为 20.11-150 mIU/l(中位数 32.95 mIU/l),中位数血清 TSH 水平为 0.36-75.17 mIU/l(中位数 7.44 mIU/l)。怀孕期间甲状腺功能减退的平均持续时间为 21.2±13.2 周(中位数 18.5 周);在 36 例(34.9%)中,所有孕期 TSH 水平均升高。不良妊娠结局包括流产 7.8%、早产 2.9%和其他并发症 14.6%,与对照组无统计学差异。怀孕期间的中位数血清 TSH 水平与流产+早产率和所有与妊娠相关并发症的发生率呈正相关(P<0.05)。
严重甲状腺功能减退症妇女的流产和早产发生率较低。即使未达到目标 TSH 水平,也可通过强化随访和 L-T₄ 治疗来改善妊娠结局。